Sens. Susan Collins (L) and Shelley Moore Capito (J. Scott Applewhite/AP Images)

Two Re­pub­li­can sen­a­tors call on CMS to not re­strict cov­er­age to amy­loid-tar­get­ed Alzheimer's drugs

Re­pub­li­can Sen­a­tors Su­san Collins of Maine and Shel­ley Moore Capi­to of West Vir­ginia re­cent­ly sent a let­ter to CMS, urg­ing the agency to not move for­ward with its re­stric­tions on cov­er­ing amy­loid-tar­get­ed Alzheimer’s drugs ahead of an April 11 dead­line for a fi­nal na­tion­al cov­er­age de­ter­mi­na­tion.

The sen­a­tors joined a grow­ing cho­rus of more than 75 mem­bers of Con­gress and oth­ers in in­dus­try, like Bio­gen and BIO, who have in­sist­ed that a CMS de­ci­sion to re­strict these new and up­com­ing Alzheimer’s drugs to on­ly clin­i­cal tri­als would “in­ap­pro­pri­ate­ly threat­en pa­tient ac­cess to treat­ment,” and “thwart ad­vances” in Alzheimer’s R&D.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.